Many do not realize the potential of mathematical and algorithmic ideas to have a societal impact through the commercial space. Mathematicians often receive advice tailored for other areas, such as building physical objects, consulting, or general software development, that may not apply. Additionally, startups with sophisticated mathematical, statistical, or engineering algorithms may encounter unique problems. In this new colloquium series, startup CEOs will discuss the story of their companies from seed to IPO stages and offer advice on building successful businesses based on mathematics or algorithms.

Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. Dr. Schadt was founder and CEO of Sema4, a predictive health company creating tools to better diagnose, treat, and prevent disease. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).

Reception with refreshments to follow talk.

Event will be in-person and on Zoom:
https://umich.zoom.us/j/98734707290

Co-sponsored by: Michigan Center for Applied and Interdisciplinary Mathematics (MCAIM), the Department of Computational Medicine and Bioinformatics (DCMB), Michigan Innovation Partnerships, and the Van Loo Symposium.